3',4'-Methylenedioxy-α-pyrrolidinopropiophenone
This is an old revision of this page, as edited by Mplanine (talk | contribs) at 23:02, 15 July 2022 (added the 3D structure to the chemical infobox). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Clinical data | |
---|---|
Routes of administration | By mouth, insufflation, Vaporization, IV, rectal, sublingual |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Hepatic |
Excretion | Primarily Urine (Renal) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H17NO3 |
Molar mass | 247.294 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
|
3',4'-Methylenedioxy-α-pyrrolidinopropiophenone (MDPPP) is a stimulant designer drug. It was sold in Germany in the late 1990s and early 2000s as an ingredient in imitation ecstasy (MDMA) pills.[1] It shares a similar chemical structure with α-PPP and MDPV,[2][3][4] and has been shown to have reinforcing effects in rats.[5]
Metabolism
MDPPP appears to have a similar metabolic fate as MDPV.[4]
Legal Status
As of October 2015[update] MDPPP is a controlled substance in China.[6]
See also
- α-Pyrrolidinopropiophenone (α-PPP)
- 4'-Methyl-α-pyrrolidinopropiophenone (MPPP)
- 4'-Methoxy-α-pyrrolidinopropiophenone (MOPPP)
- 3',4'-Methylenedioxy-α-pyrrolidinobutiophenone (MDPBP)
- Dimethylone
References
- ^ Springer D, Fritschi G, Maurer HH (August 2003). "Metabolism and toxicological detection of the new designer drug 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 793 (2): 377–88. doi:10.1016/S1570-0232(03)00350-7. PMID 12906913.
- ^ Maurer HH, Kraemer T, Springer D, Staack RF (April 2004). "Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis". Therapeutic Drug Monitoring. 26 (2): 127–31. doi:10.1097/00007691-200404000-00007. PMID 15228152. S2CID 9255084.
- ^ Staack RF, Maurer HH (June 2005). "Metabolism of designer drugs of abuse". Current Drug Metabolism. 6 (3): 259–74. doi:10.2174/1389200054021825. PMID 15975043.
- ^ a b Springer D, Staack RF, Paul LD, Kraemer T, Maurer HH (March 2005). "Identification of cytochrome P450 enzymes involved in the metabolism of 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 35 (3): 227–37. doi:10.1080/00498250400028239. PMID 16019948. S2CID 28207896.
- ^ Gannon BM, Galindo KI, Mesmin MP, Sulima A, Rice KC, Collins GT (May 2018). "Relative reinforcing effects of second-generation synthetic cathinones: Acquisition of self-administration and fixed ratio dose-response curves in rats". Neuropharmacology. 134 (Pt A): 28–35. doi:10.1016/j.neuropharm.2017.08.018. PMC 5809320. PMID 28811192.
- ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
D1-like |
| ||||||
---|---|---|---|---|---|---|---|
D2-like |
| ||||||
Phenethylamines |
|
---|---|
Amphetamines |
|
Phentermines |
|
Cathinones |
|
Phenylisobutylamines | |
Phenylalkylpyrrolidines | |
Catecholamines (and close relatives) |
|
Miscellaneous |
|
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- CS1 Chinese-language sources (zh)
- Articles with short description
- Short description matches Wikidata
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Articles containing potentially dated statements from October 2015
- All articles containing potentially dated statements
- Wikipedia articles needing clarification from September 2024
- All stub articles